HealthTree Logo
search more_vert
close
person Sign In / Create Account
Clinical Trial: Selinexor in Heavily Pretreated Myeloma Patients
Posted: Oct 21, 2016
Clinical Trial: Selinexor in Heavily Pretreated Myeloma Patients image

A new drug called Selinexor is now being tested in clinical trials for heavily pretreated multiple myeloma patients. Patients who were previously exposed to IMiDs (immunomodulators like lenalidomide or pomalidomide) or proteasome inhibitors (bortezomib, cartilzomib) and have been refractory to both an IMiD and proteasome inhibitor can join this trial. Refractory means that patients have stopped responding to a particular drug. This Phase II trial uses both selinexor and low-dose dexamethasone twice weekly and is open in 25 site locations. To learn more about this clinical trial, click here: Selinexor Clinical Trial Note: Our Myeloma Crowd Radio show on October 28th will cover this new drug. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook twitter